Mallinckrodt Plc (NYSE:MNK)

14.04
Delayed Data
As of 4:00pm ET
 +0.05 / +0.36%
Today’s Change
13.32
Today|||52-Week Range
49.12
-37.77%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Pharmaceuticals: Other
MARKET CAP
$1.4B

Company Description

Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Staines-Upon-Thames, the United Kingdom.

Contact Information

Mallinckrodt Plc
3 Lotus Park
Staines-Upon-Thames Surrey TW18 3AG
P:441784636700
Investor Relations:

Employees

Shareholders

Other institutional62.51%
Mutual fund holders49.77%
Individual stakeholders11.10%

Top Executives

Mark C. TrudeauPresident, Chief Executive Officer & Director
Frank ScholzExecutive Vice President-Global Operations
Matthew K. HarbaughChief Financial Officer & Executive Vice President
Tunde OtulanaChief Medical Officer & Senior Vice President
Steven RomanoChief Scientific Officer & EVP